ASPE.US Aspen Neuroscience, Inc. Common Stock
- Market cap
- USD 366M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ASPE.US undervalued?
Graham numberThe Graham number of Aspen Neuroscience, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aspen Neuroscience, Inc. Common Stock fundamental analysis
No fundamental analysis for Aspen Neuroscience, Inc. Common Stock yet.
Aspen Neuroscience, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aspen Neuroscience, Inc. Common Stock
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as o…
Full company profileAspen Neuroscience, Inc. Common Stock financial statements
Aspen Neuroscience, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -53.5M | -59.3M |
| EBITDA | -49.9M | -55.3M |
| Net Income | -48.6M | -62.1M |
| EPS | -1.67 | -2.13 |
| Balance Sheet | ||
| Total Assets | 90.2M | 144M |
| Total Liabilities | 248M | 361M |
| Shareholders' Equity | -158M | -217M |
| Cash & Short-term Investments | 15.2M | 82.1M |
| Cash Flow | ||
| Operating Cash Flow | -44.2M | -52.8M |
| Capital Expenditure | 2.58M | 9.69M |
| Free Cash Flow | -46.7M | -62.5M |
| Ratios | ||
| ROA | -53.8% | -43.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Aspen Neuroscience, Inc. Common Stock dividends
Aspen Neuroscience, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Aspen Neuroscience, Inc. Common Stock
- Insiders 18.28%
- Institutions 53.30%
- Public & others 28.42%
- Shares outstanding 29.1M
- Free float 13.1M
Aspen Neuroscience, Inc. Common Stock company profile
- Company name
- Aspen Neuroscience, Inc. Common Stock
- Ticker
- ASPE.US
- Exchange
- USA Stocks
- Listed since
- Oct 30, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- December
- Address
- 10835 Road to the Cure, San Diego, CA, United States, 92121
- Phone
- (858) 263-1222
- Website
- aspenneuroscience.com
About Aspen Neuroscience, Inc. Common Stock
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
Aspen Neuroscience, Inc. Common Stock management
10- Mr. Faheem HasnainExecutive Chairman · born 1958
- Dr. Damien McDevitt Ph.D.President, CEO & Director · born 1967
- Mr. Dalen Meeter C.P.A., M.B.A.Chief Financial Officer · born 1978
- Mr. Kim Raineri M.B.A.Chief Technology Officer · born 1973
- Prof. Jeanne F. Loring Ph.D.Co-Founder & Member of Scientific Advisory Board
- Ms. Xiaokui Zhang Ph.D.Chief Scientific Officer
- Mr. Jeffrey Lee Boerneke J.D.General Counsel & Secretary · born 1986
- Ms. Samantha Murphy Ph.D.Senior Vice President of Corporate Development
- Ms. Jennifer WhitakerVice President of Human Resources
- Mr. Andres Bratt-Leal Ph.D.Senior Vice President of Research & Development